Urine Osmolality Is a Potential Marker of Longer-term Efficacy of Tolvaptan in ADPKD: A Post-hoc Analysis.

Vijay D Ivaturi Jogarao V S Gobburu Bruce Leslie Xiaofeng WangPravin Jadhav

Published in: Kidney360 (2024)

Change in Uosm is a potential biomarker for long-term treatment outcome with tolvaptan and might expedite clinical trials and treatment decision-making for drugs with similar mechanisms of action.

Keyphrases

polycystic kidney disease
clinical trial
decision making
preterm infants
heart failure
risk assessment
gestational age
combination therapy
atrial fibrillation
open label
replacement therapy
smoking cessation